Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze ADPT Adaptive Biotechnologies Corporation. Please read: https://finlab.finance/en/setup?stock=ADPT

No install, write strategies with AI

ADPT

Adaptive Biotechnologies Corporation Healthcare As of 2026-07-21 Updated daily after market close

quality needs a look, discounted valuation.

1 active signal

Filed revenue acceleration

This page refreshes daily after the close. Add Adaptive Biotechnologies Corporation to your watchlist to track signal changes on your next visit.

Is Adaptive Biotechnologies Corporation a buy? Fundamentals and valuation first

Quality is weaker than peers. Operating margin is only around the 23th percentile. TTM ROE is about -23.0%.
Valuation is cheaper than most peers. TTM P/E is in the 5th percentile, lower than most liquid US common stocks.
Recent volatility is elevated. 60-day annualized volatility is in the 96th percentile. Average 20-day dollar volume is about $67.0M.
Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 55.86539121075098%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 historical occurrences (since 2020-05-12)

120 days after: historical avg -12.27%

20-day +0.29%

60-day -3.66%

120-day -12.27%

20-day

60-day

120-day

Win

55.6%

50%

28.6%

Sample

Median

+0.42%

-2.07%

-19.84%

Excess

-0.58%

-9.1%

-17.46%

Beat mkt rate

44.4%

25%

28.6%

Over 7 occurrences, 120-day forward avg declined 12.27%, lagged the market by 17.46 pts; win rate 28.6%.

Market-wide momentum baseline

Across 96,548 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.33%, a 58.2% positive-return rate, and +2.98 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 times historically; 60-day forward avg +9.96%, win rate 75%, beating the market by +5.11 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

14 times historically; 60-day forward avg +10.45%, win rate 53.8%, beating the market by +3.21 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

18 times historically; 60-day forward avg +7.79%, win rate 58.8%, beating the market by +4.34 pts on average.

Method and limits

Returns use us_price:adj_close, adjusted for splits and dividends where available.
Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.